{"groups":[{"description":"Dose of Cyclophosphamide depended on how many patients we had treated. Three participants were treated at each level:\n\n* Dose Level 1: Cyclophosphamide 250 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 2: Cyclophosphamide 500 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 3: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.0 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12\n* Dose Level 4: Cyclophosphamide 750 mg /m\\^2 IV Day 1; VELCADE, 1.3 mg/m\\^2 IV days 1,4,8, and 11; DOXIL 30 mg/m\\^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12","id":"FG000","title":"A. Phase I - Dose Escalation"},{"description":"Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.","id":"FG001","title":"B. Phase II - Maximum Planned Dose (MPD)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"46"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"46"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were recruited at Moffitt Cancer Center from September 2008 to August 2011."}